Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
Want to see TSE:EPRX full AI Analyst Report?
Top Page
Eupraxia Pharmaceuticals
(TSX:EPRX)
Select Model
Select Model
Rating:46Neutral
Price Target:
C$8.50
▼(-12.73% Downside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by pre-revenue operations, widening losses, and ongoing/accelerating cash burn that can necessitate future financing. A strengthened, low-leverage balance sheet provides some resilience, while technical indicators are neutral-to-mixed and valuation is constrained by negative earnings and no dividend data.
Positive Factors
Proprietary delivery platform
A proprietary DiffuSphere local delivery platform is a durable competitive asset: targeted, controlled‑release therapy can reduce systemic side effects, create clinical differentiation across urology and osteoarthritis, and enable multiple pipeline programs from one core technology.
Negative Factors
Pre-revenue operations
Being pre-revenue is a persistent structural constraint: the company must fund development until commercialization, has no product cash flows to offset R&D, and remains dependent on external capital, lengthening the path to positive earnings and returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary delivery platform
A proprietary DiffuSphere local delivery platform is a durable competitive asset: targeted, controlled‑release therapy can reduce systemic side effects, create clinical differentiation across urology and osteoarthritis, and enable multiple pipeline programs from one core technology.
Read all positive factors
Eupraxia Pharmaceuticals (EPRX) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$596.96M
Dividend YieldN/A
Average Volume (3M)53.43K
Price to Earnings (P/E)―
Beta (1Y)1.01
Revenue GrowthN/A
EPS Growth-34.19%
CountryCA
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.05
Shares Outstanding65,326,950
10 Day Avg. Volume45,847
30 Day Avg. Volume53,430
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)5.04
Price to Sales (P/S)0.00
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$23.10Price Target Upside137.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.17
Revenue Forecast (FY)N/A
Eupraxia Pharmaceuticals Business Overview & Revenue Model
Company Description
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical trial, tar...
How the Company Makes Money
null...
Eupraxia Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -218.90K | -241.88K | -163.47K | -158.05K | -193.27K | -111.53K |
| EBITDA | -44.63M | -38.86M | -23.43M | -28.16M | -22.14M | -21.96M |
| Net Income | -42.19M | -39.25M | -24.28M | -28.15M | -23.26M | -22.99M |
Balance Sheet | ||||||
| Total Assets | 145.46M | 85.99M | 34.94M | 20.12M | 25.88M | 31.22M |
| Cash, Cash Equivalents and Short-Term Investments | 138.98M | 80.42M | 33.10M | 19.34M | 24.74M | 29.90M |
| Total Debt | 2.01M | 154.08K | 71.86K | 10.45M | 10.55M | 9.49M |
| Total Liabilities | 9.17M | 5.69M | 4.46M | 19.23M | 14.51M | 11.67M |
| Stockholders Equity | 137.88M | 81.89M | 33.40M | 1.67M | 12.86M | 20.39M |
Cash Flow | ||||||
| Free Cash Flow | -32.14M | -29.65M | -30.10M | -21.09M | -19.08M | -15.07M |
| Operating Cash Flow | -31.41M | -29.05M | -29.99M | -21.02M | -18.78M | -14.64M |
| Investing Cash Flow | -79.15M | -599.26K | -75.16K | -73.20K | 8.70M | -14.45M |
| Financing Cash Flow | 122.16M | 77.39M | 45.78M | 20.96M | 13.52M | 49.92M |
Eupraxia Pharmaceuticals Technical Analysis
Negative
9.74
Price Trends
9.59
Negative
10.15
Negative
9.57
Negative
Market Momentum
-0.26
Negative
48.95
Neutral
90.69
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Negative. The current price of 9.74 is above the 20-day moving average (MA) of 9.09, above the 50-day MA of 9.59, and above the 200-day MA of 9.57, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 48.95 is Neutral, neither overbought nor oversold. The STOCH value of 90.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:EPRX.
Eupraxia Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
TSE:EPRX
Eupraxia Pharmaceuticals
9.06
3.14
53.04%
TSE:DRUG
Bright Minds Biosciences
87.58
50.05
133.36%
TSE:MYND
MYND Life Sciences
0.07
0.00
0.00%
TSE:MBIO
Mindbio Therapeutics Corp.
0.43
-3.57
-89.25%
Eupraxia Pharmaceuticals Corporate Events
Business Operations and Strategy
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences
Positive
Apr 15, 2026
Eupraxia Pharmaceuticals, a clinical-stage biotech specializing in locally delivered, extended-release drugs based on its Diffusphere microsphere technology, is advancing a pipeline that includes EP-104GI for eosinophilic esophagitis and EP-104IAR...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.